Lysosomal storage disorder – Diagnostics – Overview of Information and Clinical Research

When someone experiences unusual symptoms affecting multiple body systems, or when a child shows developmental delays alongside organ enlargement, doctors may suspect a lysosomal storage disorder. Understanding how these rare genetic conditions are diagnosed can help families navigate the testing process and seek care at the right time.

Introduction: Who Should Undergo Diagnostics and When

Lysosomal storage diseases typically appear during pregnancy or infancy, though adults can also develop these conditions. Because these disorders affect how cells break down essential substances like fats and sugars, they can cause problems throughout the body. Early diagnosis is essential because treatments work best when started before significant organ damage occurs.^[1]

Parents should consider seeking diagnostic testing if their child shows delays in intellectual and physical development, seizures, facial and bone deformities, or joint stiffness and pain. These symptoms may develop gradually as toxic materials accumulate in cells over time.^[4] Because the body’s organs become more affected as storage builds up, recognizing these warning signs early can make a significant difference in outcomes.

Adults may also need testing if they develop progressive symptoms affecting the heart, kidneys, nervous system, or other organs, especially if they have a family history of lysosomal storage diseases. Some ethnic groups face higher risk—for example, people of Eastern European Jewish descent and those from Finland have increased rates of certain lysosomal storage disorders.^[1] Knowing your family background can help doctors determine whether testing is appropriate.

Healthcare providers typically recommend diagnostic testing when they observe a pattern of symptoms that suggests an LSD, when screening tests show abnormal enzyme levels, or when prenatal testing reveals potential concerns. Because these conditions are rare individually, it can take time for doctors to consider them, sometimes requiring years to rule out other possibilities before confirming a lysosomal storage disease.^[8]

Diagnostic Methods for Identifying Lysosomal Storage Diseases

Enzyme testing is usually the first diagnostic approach for lysosomal storage diseases. Since most of these conditions result from missing or deficient enzymes, measuring enzyme activity levels in the blood can reveal whether the body lacks the specific protein needed to break down fats, sugars, or other substances. Healthcare providers take a simple blood sample, which specialized laboratories analyze to determine if enzyme levels are normal or dangerously low.^[2]

For some lysosomal storage diseases, doctors may also test for enzyme deficiencies using samples of cultured skin cells called fibroblasts, or they may analyze white blood cells from the blood. Different diseases require testing for different enzymes—for example, Gaucher disease involves testing for glucocerebrosidase activity, while Fabry disease requires measuring alpha-galactosidase A levels.^[6]

⚠️ Important

Enzyme testing provides reliable results for most lysosomal storage diseases, but some conditions may require additional testing methods. Enzyme activities may not be reliable in premature newborns with less than 34 weeks gestation or birthweight under 2000 grams, requiring a repeat screen at 28 days of age.^[5]

Genetic testing and DNA analysis add precision to diagnosis by identifying the specific gene mutations causing the enzyme deficiency. Most lysosomal storage diseases are autosomal recessive disorders, meaning a person must inherit a mutated gene from both parents to develop the condition. Genetic testing can confirm which specific mutation is present, helping doctors predict disease severity and progression.^[2]

Urine tests can also help diagnose certain types of lysosomal storage diseases, particularly the mucopolysaccharidoses. These conditions cause elevated levels of complex sugar molecules called glycosaminoglycans in the urine. Doctors measure total and fractionated urinary glycosaminoglycans to identify abnormal patterns that suggest a specific disorder.^[6]

For pregnant women with family histories of lysosomal storage diseases, prenatal testing offers the opportunity to diagnose these conditions before birth. Two main prenatal testing methods exist: amniocentesis, which involves taking a sample of the fluid surrounding the fetus, and chorionic villus sampling, which takes a sample of placental tissue. Both methods allow genetic analysis and enzyme testing on fetal cells.^[4]^[18]

Some regions now include lysosomal storage disease screening in their newborn screening programs. These programs test dried blood spots from newborns for enzyme deficiencies in conditions like Pompe disease, Gaucher disease, Fabry disease, MPS I, MPS II, and Krabbe disease. The optimal collection time for these samples is between 24 and 48 hours of age.^[5]

Beyond enzyme and genetic testing, doctors use various additional diagnostic methods to assess organ damage and disease progression. Imaging tests like X-rays can reveal characteristic bone abnormalities called dysostosis multiplex that appear in many lysosomal storage diseases. A skeletal survey, which includes multiple X-ray images of different bones, helps identify these changes.^[6]

Heart function testing through echocardiography checks for valve disease and other cardiac complications common in lysosomal storage diseases. Hearing tests called audiometry detect hearing changes that can accompany these conditions. Blood tests monitoring liver and kidney function help doctors track how the disease affects these vital organs.^[6]^[18]

Because lysosomal storage diseases can be difficult for physicians to diagnose—since symptoms vary among different types and individual disorders are rare—specialized lysosomal disease testing laboratories offer specific tests that can confirm or rule out suspected conditions. The diagnostic process may take time while doctors recognize symptom patterns and rule out other diseases.^[8]

Diagnostics for Clinical Trial Qualification

When patients consider participating in clinical trials for lysosomal storage diseases, they must undergo specific diagnostic testing to determine eligibility. Clinical trials require precise confirmation of diagnosis to ensure participants actually have the condition being studied and to establish baseline measurements for tracking treatment effects.

Enzyme analysis remains the foundation of clinical trial qualification. Trial protocols typically specify the exact enzyme deficiency levels required for enrollment. For example, a trial studying enzyme replacement therapy would need documented proof that the participant has significantly reduced or absent activity of the specific enzyme that the therapy aims to replace.^[2]

Genetic testing serves as another standard criterion for enrolling patients in clinical trials. Researchers often require DNA analysis confirming specific gene mutations associated with the lysosomal storage disease under investigation. This genetic confirmation ensures that participants have the precise molecular defect that the experimental treatment targets. Some trials may only accept patients with certain mutation types, making detailed genetic analysis essential.^[18]

Clinical trials typically require comprehensive baseline assessments of organ function before treatment begins. These assessments create a reference point for measuring whether the experimental therapy produces improvements. Baseline testing commonly includes echocardiograms to document heart function, blood tests to measure liver and kidney function, and imaging studies to assess organ size and tissue damage.^[18]

Developmental assessments may be required for pediatric clinical trials. Researchers document intellectual and physical developmental milestones before treatment to track whether experimental therapies help prevent or slow developmental delays. Regular monitoring during the trial compares these ongoing measurements to baseline values.^[18]

Some clinical trials investigating advanced therapeutic techniques require additional specialized testing. Trials studying gene therapy approaches may need detailed genetic analysis of multiple gene variants. Studies examining new diagnostic methods might require participants to undergo both established and experimental testing procedures for comparison purposes.^[2]

⚠️ Important

Clinical trial eligibility criteria vary significantly between studies. Each trial protocol defines specific diagnostic requirements based on the treatment being tested and the research questions being asked. Meeting with a metabolic specialist and clinical trial coordinator helps families understand which tests their loved one needs for participation consideration.^[18]

Family history documentation often forms part of clinical trial qualification. Researchers may request information about relatives with similar conditions or genetic testing of family members to understand inheritance patterns. This information helps ensure proper patient selection and may provide valuable data for understanding how genetic factors influence treatment responses.

Ongoing monitoring throughout clinical trials requires repeated diagnostic testing at specified intervals. Trial participants typically undergo the same enzyme, genetic, and organ function tests performed at baseline, allowing researchers to track changes over time. The frequency and types of follow-up testing depend on the specific trial protocol and the treatment being studied.^[18]

Prognosis and Survival Rate

Prognosis

The outlook for people with lysosomal storage diseases varies considerably depending on the specific disorder, the age when symptoms begin, and how quickly treatment starts. Generally, people experience more severe disease when symptoms appear early in infancy, while those who develop symptoms later in childhood or adulthood tend to have milder courses.^[1] For example, a child’s developing brain is particularly vulnerable to damage from toxic substance buildup, leading to more severe neurological symptoms compared to adults with the same condition.^[2]

The organs where toxic materials accumulate determine which complications develop. Because different lysosomal storage diseases affect different organ systems, prognosis depends heavily on which parts of the body bear the greatest burden. Diseases affecting the brain typically have more serious outcomes because nerve damage is often irreversible. Conditions primarily affecting the liver, spleen, or bones may have better outcomes with treatment.^[1]

Early diagnosis significantly improves prognosis because treatments work best when started before substantial organ damage occurs. Modern therapies including enzyme replacement therapy, substrate reduction therapy, and stem cell transplantation can prevent or delay damage, improve quality of life, and increase lifespan when applied before irreversible harm sets in.^[2] Without treatment, lysosomal storage diseases are progressive, meaning they worsen over time. The rate of progression and severity vary among different disorders and even within each disorder type.^[8]

Factors affecting prognosis include the specific type of enzyme deficiency, the degree of residual enzyme activity remaining in the body, access to specialized medical care, and the availability of disease-specific treatments. Some lysosomal storage diseases now have approved therapies that can substantially alter disease progression, while others still lack specific treatments beyond supportive care.^[18]

Survival Rate

Survival rates for lysosomal storage diseases vary dramatically depending on the specific condition and its severity. Some forms are rapidly fatal in infancy without treatment, while others allow individuals to live into adulthood with appropriate medical management. Many lysosomal storage diseases, particularly those with severe early-onset forms, can lead to death in infancy or childhood if left untreated.^[4]

The introduction of enzyme replacement therapy and other specific treatments has significantly improved survival for some conditions. However, specific survival statistics vary by disorder type and are continually evolving as new treatments become available. Infants and children generally face higher mortality than adults with the same conditions because their developing bodies are more vulnerable to the effects of toxic substance accumulation.^[2]

The last decade has brought tremendous advances in understanding and treating many lysosomal storage diseases. These advances have shown promise in improving lifespan and quality of life, which previously remained poor. When treatments are applied early before organ damage becomes extensive, they have the potential to prevent or delay complications and extend survival.^[2]

#1 Clinical Trials Search in Europe